Excited to share our work on TAPIR, a generalizable ML model that can predict TCR-target interaction!
T-cell receptors (TCRs) are involved in most diseases, but linking their sequences with targets is an unsolved grand challenge in the field.
https://t.co/TYLO873Flx
As simple as ABCD - Autoimmune central B12 deficiency: autoantibodies vs transcobalamin receptor cause depletion of B12 in the CSF with typical s/sx of B12 deficiency in patients with normal serum B12
You don’t see a paper like this every day - discovery of a new disease, guided by a peculiar patient story, complete with molecular characterization:
https://t.co/FHcxJs4mEM
This is what translational research should look like. @jvpluv strikes again
It was an honor to have you hood me x2 and learn from you during my PhD @CarolynBertozzi. Your commencement speech was fantastic, complete with wisdom from your own experience and the infamous Walter White!
Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. https://t.co/EKzcX4JaFP
BREAKING NEWS:
The Royal Swedish Academy of Sciences has decided to award the 2022 #NobelPrize in Chemistry to Carolyn R. Bertozzi, Morten Meldal and K. Barry Sharpless “for the development of click chemistry and bioorthogonal chemistry.”
A beautiful piece on dealing with death and loss by @tpjmd “Shared presence - really being there with and for each other - at a moment of loss can sanctify sorrow. Some alchemy can wring from the stone of shared suffering something like love.” https://t.co/0Ga1OIzrMN
My lab at Stanford is hiring. We work on engineering new cancer immunotherapies and understanding their activity in early phase trials. Open postdoc positions as well as a technician with animal experience. Contact me if interested! Please retweet!
Happy to share our lab's first manuscript. In work led by @JTheruvath_MD, we tested a combo of FDA approved anti-GD2 with blockade of CD47, a macrophage checkpoint. Blocking CD47 unleashes patients' macrophages to phagocytose or 'eat' cancer cells. Combo was highly effective! 1/
Excited to share our new paper in @ScienceTM where we find an oligodendrocyte derived protein in CSF impairs microglial lysosome function https://t.co/kWxLDzzykY
If anyone out there is doing glyco work with Illustrator, I have something for you! It’s a library of glycans for dropping into whatever you’re working on, as well as the SNFG colour palette. If you follow the lib, you can get updates as I make them!
https://t.co/RgsBXT58Rk
"Importantly, while screening multiple mice in parallel increases the power to discover significant hits, a single mouse is sufficient to identify significantly enriched and depleted genes."
We are thrilled to share our development of genome-wide CRISPR screening within a living mouse! Our approach is accessible to diverse phenotypes and we look forward to the many insights now achievable with high-throughput functional genomics in an organ! https://t.co/ffdMfERvbY
Calling all #glycotime fanatics! I'd like to introduce you to the #mucinome! We can now selectively enrich proteins that have mucin domains, and we developed a mucin candidacy algorithm (@riley_nm1) to assign confidence to our hits. @CarolynBertozzi 🧵👇https://t.co/eFSvr8MtBL
It's 2021 and cultures, which take weeks, are still the gold standard for TB diagnosis. This is another step toward solvatochromatic probes becoming the standard of care @mkamariza2002 and @Peyton_Shieh
Show stopper: these are TB-causing cells detected with our #DMN-Tre probe in ***blood samples*** - a first!
The paper is in the works and stay tuned for the preprint.
Pic credit: @davidadambarr from @graemein lab.
#StopTB#SmartProbes#TBDx
@CarolynBertozzi and I reviewed the landscape of therapies targeting mammalian #glycans, #siglecs and #selectins, focusing on discoveries that launched new drug development campaigns, lessons learned, and promising candidates to watch. Keep your eye on the #glycotime pipeline!
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans https://t.co/D1tPsVANyV - this new review by Benjamin Smith and @CarolynBertozzi highlights experience and therapeutic opportunities in a field that is becoming increasingly tractable